Novartis

After Novartis Pact, Macrocycle Shop Unnatural Products Gets $45M Series B

Novartis, SciNeuro to Work Together on Preclinical Amyloid-Targeting Drug for Alzheimer’s

Isomorphic Labs Raises $2.1 B to Expand AI-Driven Drug Discovery Platform

Keep an Eye on These 15 Biotech Companies in 2026 

Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave Crashes

Roche Breast Cancer Prospect Fails First-Line Test, Shares Fall

After Exiting 2seventy, Chip Baird Took a 180 to Food Allergy With Newly Launched Poplar

STAT+: Pharmalittle: We’re Reading About FDA Seeking More Data on a Lilly Obesity Pill, a Pharma 340B Win, and More

Novartis Breaks Ground on San Diego Biomedical R&D Site

4 Spaces Primed for the Next Wave of Gene Therapies

Biotech in 2025: A Retrospective 

UAE Exits OPEC, Iran Peace Talks Spark Mixed Moves in European Stocks

Burnout Common but Regrets Are Not in Allergy, Immunology

Celcuity’s Gedatolisib Beats Novartis’ Piqray in Phase III Advanced Breast Cancer Trial

Health Care Roundup: Market Talk

Iridius Raises $8.6M Seed Round to Build Compliance-by-Design AI Platform for Regulated Enterprise Workflows

Vertex Secures German Reimbursement Deal for CASGEVY Gene Therapy

STAT+: Novartis CEO Joins Anthropic’s Board

TerraPower Commits $450M to Build Radioisotope Production Plant

Anti-Amyloid Alzheimer’s Drugs Show Limited Benefit in Cochrane Review

Novartis Licenses Radiopharma Asset From Chinese Biotech for $50M Upfront

Telix, Regeneron Ink $40M 50/50 Deal to Co‑Develop Next‑Gen Radiopharmaceuticals

FDA Drug Safety Communication: New Warning and Contraindication for Blood Pressure Medicines Containing Aliskiren (Tekturna)

GSK Reports Promising Early Results in Ovarian and Womb Cancer Drug Trial

Alphabet's Isomorphic Labs Raises $2.1 Billion to Scale AI Drug Discovery Toward Clinical Trials

This Sam Altman-Backed $1.8 Billion Startup Bets AI Can Get Drugs Through Clinical Trials Faster

AstraZeneca Leads Big Pharma’s AI Clinical Trials Revolution with Real-World Patient Impact

Novartis Reveals More Data Behind Pluvicto Expansion Bid

Novartis Slashes 114 More Jobs at New Jersey HQ

Novartis' Radioligand Therapy Lutathera Could Soon Face Generic Competition

Fragment Merging – and Flipping – on the Leucine Zipper of MITF

Orion Properties Leases Full Irving Office Building: The DFW Deal Sheet

Novartis to Buy US-Based Biotech Firm Excellergy for up to US$2 Billion

Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100

FDA Approves Incyte’s Once‑Daily Jakafi XR for Myelofibrosis, Polycythemia Vera and GVHD

Novartis Antimalarial Clears Key WHO Review to Get the Combo Drug to Babies

Insufficient Source Data to Report on Novartis‑Excellergy Deal

Novartis CEO Joins Board of "Responsible" AI Firm Anthropic

The Company that Built TikTok’s Algorithm Is Now Designing Drugs for Diseases Pharma Called Undruggable

Trump’s New Drug Advertising Proposals Fall Short on Public Health and the Constitution

STAT+: Boehringer’s Obesity Drug Shows 16.6% Weight Loss; More Data Needed

JPM26: Filling C-Suites, Union Square—And Elevators—With Pink

Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal

Novartis' Rhapsido Wins EU Approval as First Oral Treatment for Chronic Spontaneous Urticaria

Amgen Adds $300M to Puerto Rico Budget; Novartis to Exit Oral Drug Factory in Germany

Inclisiran Linked to Lower MACE, AMI Rates in High-Risk ASCVD Population

Merck Inks $1 B Multi‑year AI Pact with Google Cloud

MSD-Backed Ray Locks in $125m to Back Eye Drug Pipeline

Health Equity & Access Weekly Roundup: February 20, 2026

Ocrelizumab Preserves Ambulation, Hand Function in MS

Novartis to Acquire Experimental Breast Cancer Drug From Synnovation Therapeutics for $2B

Novartis to Acquire Avidity Biosciences in $12B Takeover

Novartis to Sell 70.68% Stake in Novartis India to Consortium for ₹1,446 Crore

Unnatural Products Secures $1.8B Cardio Pact with Novartis